Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

British journal of haematology·2026
Same author

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Blood advances·2026
Same author

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Blood advances·2026
Same author

BATF3 regulates differentiation of CD8<sup>+</sup> T lymphocytes and memory differentiation program.

Life science alliance·2026
Same author

Ponatinib inhibits LCK and PI3K signaling and promotes CD8<sup>+</sup> T stem cell memory cell development.

Nature communications·2026
Same author

CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis.

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Jun 15, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Recent advances in AML with mutated NPM1.

Yuichi Ishikawa1, Yoko Ushijima2, Hitoshi Kiyoi2

  • 1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan. yishikaw@med.nagoya-u.ac.jp.

International Journal of Hematology
|August 22, 2024
PubMed
Summary
This summary is machine-generated.

Nucleophosmin 1 (NPM1) mutations are common in acute myeloid leukemia (AML). These NPM1 mutations impact AML classification, prognosis, and targeted therapy development.

Keywords:
NPM1 mutationAMLMolecular targeted therapyPathogenesisPrognosis

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

40
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.5K

Related Experiment Videos

Last Updated: Jun 15, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

40
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.5K

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Nucleophosmin 1 (NPM1) mutations are prevalent in adult acute myeloid leukemia (AML), especially in normal karyotype AML.
  • Mutant NPM1 proteins show altered cytoplasmic localization compared to wild-type nuclear localization.
  • NPM1 mutations define a distinct genetic entity in AML with significant clinical implications.

Purpose of the Study:

  • To review recent advancements in the clinical and biological understanding of NPM1 mutations in AML.
  • To highlight the significance of NPM1 mutations in AML classification, prognosis, and response assessment.
  • To discuss emerging molecular targeted therapies for NPM1-mutated AML.

Main Methods:

  • Literature review of recent studies on NPM1 mutations in AML.
  • Analysis of clinical data regarding prognosis and remission rates in NPM1-mutated AML.
  • Examination of biological roles and therapeutic strategies related to NPM1.

Main Results:

  • AML with NPM1 mutations, particularly without FLT3-ITD, shows higher complete remission rates and improved survival.
  • NPM1 mutations are crucial for AML classification and prognosis.
  • Measurable residual disease monitoring and targeted therapies (menin and XPO-1 inhibitors) show clinical utility.

Conclusions:

  • NPM1 mutation is a key factor in AML, influencing classification, prognosis, and treatment strategies.
  • Targeting NPM1 mutations offers promising avenues for molecular therapy in AML.
  • Further research into NPM1's role in hematopoiesis and AML development is warranted.